



## **AEGERA THERAPEUTICS INC. APPOINTS DONALD OLDS AS CHIEF FINANCIAL OFFICER**

MONTREAL, QC, CANADA. *September 25, 2002.* Aegera Therapeutics Inc. is pleased to announce the appointment of Mr. Donald Olds to the company's executive management team. Donald joins Aegera as Vice-President, Finance and Chief Financial Officer.

Donald brings over 12 years of corporate finance experience spanning both private and public corporations, as well as financial institutions. Most recently, he was Chief Financial Officer at Mediatrix Telecom Inc., a private Quebec-based telecommunications company, which successfully completed two private equity financings raising in excess of \$30 million.

Previously, Donald led the Quebec technology practice of TD Securities Inc., where he was instrumental in bringing forward a variety of public and private debt, equity, merger and acquisition transactions.

"We are excited to have Donald to complete our senior management team," commented Michael Atkin, Aegera's Chief Executive Officer, "his strong skill set, combining corporate finance and investment banking with public and private company experience, provides the ideal experience base needed to ensure Aegera's continuing growth and success."

Donald will be responsible for leading Aegera's day-to-day financial operations, as well as for spear-heading Aegera's future financing rounds.

Donald is a two-time graduate of McGill University, with a Masters of Science (1987) and Masters of Business Administration (1991).

### **About Aegera**

Aegera Therapeutics Inc. is a privately-held biotechnology company headquartered in Montreal, Canada, with a wholly owned subsidiary – Aegera Oncology Inc. Aegera has built a strong, focused biotechnology company focused on apoptosis control to extend and enhance life: killing cancer cells by inducing apoptosis and rescuing neurons from cell death. Its lead oncology program is a XIAP antisense therapeutic which is expected to enter the clinic in Q1 2004. Aegera has in development two additional approaches to regulate apoptosis for cancer. In addition, it is also developing small molecular drugs to treat central and peripheral nerve diseases as well as a unique adult stem cell technology. For more information, please visit Aegera's website at [www.aegera.com](http://www.aegera.com).